Friday, 17 April 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 17 April 2026
News

No TGA action after patient deaths

 Posted 17 April 2026 PM

With both the FDA and EMA taking action over PBS-listed Tavneos following the deaths of eight people overseas, news that the TGA is taking a wait-and-see approach was our top story this week.

The Amgen drug, sponsored by CSL in Australia, is the subject of an FDA warning alerting patients and HCPs about "serious postmarketing cases, including fatal cases of drug induced liver injury". The EMA meanwhile is reviewing the drug's approval.

To see the whole article, please login

Popular

Pfizer names local as Interim MD
Patient fury over pricing standoff
Time for a tough conversation
New hurdle for Novartis therapy
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (14)

Clinical & Medical, R&D (8)

Regulatory, Pharmacovigilance & QA (3)

Other (8)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home